Epstein-Barr virus: The impact of scientific advances on clinical practice

Blood

Volumn 107, Issue 3, 2006, Pages 862-869

  Williams, Hilary ^b   Crawford, Dorothy H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CYTOKINE; EPSTEIN BARR VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2;

ANTIGEN EXPRESSION; CLINICAL FEATURE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; INFECTIOUS MONONUCLEOSIS; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; T CELL LYMPHOMA; TRANSACTIVATION; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY;

EID: 31544432829     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2702     Document Type: Review

References (106)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;15:702-703.
2. Pope JH, Horne MK, Scott W. Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer. 1968;3:857-866.
3. Pattengale PK, Smith RW, Gerber P. Selective transformation of B lymphocytes by EB virus. Lancet. 1973;2:93-94.
4. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci. 2001;356:461-473.
5. Hoagland RJ. The transmission of infectious mononucleosis. Am J Med Sci. 1955;229:262-272.
6. Henle G, Henle W, Diehl V. Relation of Burkitt's tumour-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci U S A. 1968;59:94-101.
7. Niederman JC, Evans AS, Subrahmanyan L, McCollum RW. Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med. 1970;282:361-365.
8. Sawyer RN, Evans AS, Niederman JC, McCollum RW. Prospective studies of a group of Yale University freshmen, I: occurrence of IM. J Inf Dis. 1971;123:263-270.
9. University Health Physicians and Public Health Laboratory Service Laboratories. Infectious mononucleosis and its relationship to EB virus antibody. Brit Med J. 1971;4:643-646.
10. Hallee TJ, Evans AS, Niederman JC, Brooks CM, Voegtly H. Infectious mononucleosis at the US Military Academy: a prospective study of a single class over four years. Yale J Biol Med. 1974;47:182-195.
11. Crawford DH, Swerdlow AJ, Higgins C, et al. Sexual history and Epstein-Barr virus infection. J Infect Dis. 2002;186:731-736.
12. Sixbey JW, Lemon SM, Pagano JS. A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet. 1986;2:1122-1124.
13. Israele V, Shirley P, Sixbey JW. Excretion of the Epstein-Barr virus from the genital tract of men. J Infect Dis. 1991;163:1341-1343.
14. Kapranos N, Petrakou E, Anastasiadou C, Kotronias D. Detection of herpes simplex virus, cytomegalovirus, and Epstein-Barr virus in the semen of men attending an infertility clinic. Fertil Steril. 2003;79(suppl 3):1566-1570.
15. White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry. 1998;173:475-481.
16. White PD, Thomas JM, Kangro HO, et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet. 2001;358:1946-1954.
17. Swanink CM, van der Meer JW, Vercoulen JH, Bleijenberg G, Fennis JF, Galama JM. Epstein-Barr virus (EBV) and the chronic fatigue syndrome: normal virus load in blood and normal immunologic reactivity in the EBV regression assay. Clin Infect Dis. 1995;20:1390-1392.
18. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood. 1995;85:744-750.
19. Thorley-Lawson DA, Gross A. Mechanisms of disease: persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328-1337.
20. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A. 2004;101:239-244.
21. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol. 2004;78:5194-5204.
22. Vetsika EK, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med. 2004;6:1-16.
23. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol. 2000;54:19-48.
24. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol. 1987;139:3802-3807.
25. + T cells in acute infectious mononucleosis. Nat Med. 1996;2:906-911.
26. +-activated T cells in primary EBV infection. J Immunol. 1999;163:5735-5740.
27. Foss HD, Herbst H, Hummel M, et al. Patterns of cytokine gene expression in infectious mononucleosis. Blood. 1994;83:707-712.
28. Biglino A, Sinnico A, Forno B, et al. Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. Clin Immunol Immunopathol. 1996;78:61-69.
29. Williams H, Macsween K, McAulay K, et al. Analysis of immune activation and clinical events in acute infectious mononucleosis. J Infect Dis. 2004;190:63-71.
30. Sutkowski N, Palkama T, Ciurli C, Sekaly RP, Thorley-Lawson DA, Huber BT. An Epstein-Barr virus-associated superantigen. J Exp Med. 1996;184:971-980.
31. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med. 1998;187:1395-1402.
32. + T cells during primary infection. J Immunol. 2003;170:2590-2598.
33. Williams H, McAulay K, Macsween KF, et al. The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol. 2005;129:266-274.
34. Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev. 2004;18:193-209.
35. Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev. 1999;170:49-64.
36. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129-135.
37. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395:462-469.
38. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998;95:13765-13770.
39. Gaspar HB, Sharifi R, Gilmour KC, et al. X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. Br J Haematol. 2002;119:585-595.
40. Seemayer TA, Gross TG, Egeler RM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38:471-478.
41. Aversa G, Carballido J, Punnonen J, et al. SLAM and its role in T cell activation and Th cell responses. Immunol Cell Biol. 1997;75:202-205.
42. García VE, Quiroga MF, Ochoa MT, et al. Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J Immunol. 2001;167:5719-5724.
43. Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol. 1999;162:6981-6985.
44. Sayos J, Martin M, Chen A, et al. Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. Blood. 2001;97:3867-3874.
45. Bottino C, Falco M, Parolini S, Marcenaro E, Augugliaro R, Sivori S, et al. GNTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med. 2001;194:235-246.
46. Nichols KE, Koretzky GA, June CH. SAP: natural inhibitor or grand SLAM of T cell activation? Nat Immunol. 2001;2:665-666.
47. Latour S, Gish G, Helgason CD, Humphries RK, Pawson T, Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol. 2001;2:681-690.
48. H2 cytokine regulation. Immunity. 2004;21:707-717.
49. Valiante NM, Lienert K, Shilling HG, Smits BJ, Parham P. Killer cell receptors: keeping pace with MHC class I evolution. Immunol Rev. 1997;155:155-164.
50. Nakajima H, Cella M, Bouchon A, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol. 2000;30:3309-3318.
51. Parolini S, Bottino C, Falco M, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000;192:337-346.
52. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med. 1998;188:2083-2090.
53. Thorley-Lawson DA, Ianelli C, Klaman LD, Staunton D, Yokoyama S. Function of CD48 and its regulation by Epstein-Barr virus. Biochem Soc Trans. 1993;21:976-980.
54. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93:190-197.
55. Tabata Y, Villanueva J, Lee SM, et al. Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood. 2005;105:3066-3071.
56. Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R. SAP is required for generating long-term humoral immunity. Nature. 2003;421:282-287.
57. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118-3125.
58. Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005;105:994-996.
59. Katano H, Ali MA, Patera AC, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood. 2004;103:1244-1252.
60. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280-286.
61. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187:527-533.
62. Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet. 2000;356:223-224.
63. Kawa K, Okamura T, Yasui M, Sato E, Inoue M. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Crit Rev Oncol Hematol. 2002;44:251-257.
64. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059-4066.
65. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridisation studies in posttransplant lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis. 1985;152:876-886.
66. Thomas JA, Hotchin N, Allday MJ, et al. Immunohistology of Epstein-Barr virus associated antigens in B cell disorders from immunocompromised individuals. Transplantation. 1990;49:944-953.
67. Swerdlow AJ, Higgins CD, Hunt BJ, et al. Risk of lymphoid neoplasia after cardiothoracic transplantation: a cohort study of the relation to Epstein-Barr virus. Transplantation. 2000;69:897-904.
68. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol. 1998;16:2052-2059.
69. Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29-44.
70. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JLC. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood. 1993;81:1393-1403.
71. Timms JM, Bell A, Flavell JR, et al. Target cells of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet. 2003;361:217-223.
72. Perera SM, Thomas JA, Burke M, Crawford DH. Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. J Pathol. 1998;184:177-184.
73. Johannessen I, Asghar M, Crawford DH. Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice. Brit J Haematol. 2000;109:600-610.
74. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98:972-978.
75. Wagner NJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979-3981.
76. Baiocchi OC, Colleoni GW, Caballero OL, Vettore AL, Andrade AL, Pestana JO. Quantification of Epstein-Barr viral load and determination of a cutoff value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. Haematologica. 2004;89:366-368.
77. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364-4369.
78. Hopwood PA, Brooks L, Parratt R, et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation. 2002;74:194-202.
79. Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis. 2003;188:1853-1864.
80. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation, Lancet. 1995;345:9-12.
81. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
82. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592-2598.
83. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A. 1999;96:10391-10396.
84. Sherritt MA, Bharadwaj M, Burrows JM, et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation. 2003;75:1556-1560.
85. Wilkie GM, Taylor C, Jones MM, et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother. 2004;27:309-316.
86. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436-441.
87. Wynn RF, Arkwright PD, Haque T, et al. Treatment of Epstein-Barr-virus- associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol. 2005;6:344-346.
88. Gutersohn M, Cole P. Epidemiology of Hodgkin's disease. Semin Oncol. 1980;7:92-102.
89. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and EBV: altered antibody pattern before diagnosis. N Engl J Med. 1989;320:696-701.
90. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987;129:86-91.
91. Wu T-C, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer. 1990;46:801-804.
92. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med. 2003;349:1324-1332.
93. Murray PG, Billingham LJ, Hassan HT, et al. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood. 1999;94:442-447.
94. Glavina-Durdov M, Jakic-Razumovic J, Capkun V, Murray P. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer. 2001;84:1227-1234.
95. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337:320-322.
96. Marafioti T, Hummel M, Foss H-D, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal centre B cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443-1450.
97. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762.
98. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease. J Exp Med. 2004;200:1623-1633.
99. Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004;100:1892-1901.
100. Nemerow GR, Siaw MF, Cooper NR. Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J Virol. 1986;58:709-712.
101. Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987;50:203-213.
102. Gu SY, Huang TM, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand. 1995;84:171-177.
103. Denis M, Haumont H, Bollen A. Vaccination against Epstein-Barr virus (EBV): report of phase II studies using recombinant viral glycoprotein gp350 in healthy adults (abstract). 11th Biennial Conference of The International Association for Research on Epstein-Barr Virus and Associated Diseases, September 2004, Regensburg, Germany.
104. Duraiswamy J, Sherritt M, Thomson S, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood. 2003;101:3150-3156.
105. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol. 1997;158:3325-3334.
106. Meij P, Leen A, Rickinson AB, et al. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer. 2002;99:93-99.